PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	252-255	estrogen receptor 2	Rattus norvegicus	155-177	
22266284-0	2012	Estrogen receptor-beta agonist diarylpropionitrile counteracts the estrogenic activity of estrogen receptor-alpha agonist propylpyrazole-triol in the mammary gland of ovariectomized Sprague Dawley rats.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	122-142	estrogen receptor 2	Rattus norvegicus	0-22	
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	49-69	estrogen receptor 2	Rattus norvegicus	155-177	
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	71-74	estrogen receptor 2	Rattus norvegicus	155-177	
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	252-255	estrogen receptor 2	Rattus norvegicus	179-185	
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	252-255	estrogen receptor 2	Rattus norvegicus	179-185	
22213775-7	2012	The ERalpha and ERbeta agonists PPT and DPN show a similar neuroprotective effect to that of 17beta-E(2), but DPN is more efficient.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	32-35	estrogen receptor 2	Rattus norvegicus	16-22	
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	16-35	estrogen receptor 2	Rattus norvegicus	123-129	
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	37-40	estrogen receptor 2	Rattus norvegicus	123-129	
17075034-6	2006	We determined that E2 receptor (ER) beta mediates the effect of E2, because activation of ERbeta with diarylpropionitrile (50 pmol) attenuated the response by 57%, whereas activation of ERalpha with propyl-pyrazole-triol (20 pmol) had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	199-220	estrogen receptor 2	Rattus norvegicus	19-40	
31711895-8	2020	Similarly, ERalpha-agonism (PPT) increased Fos and Homer1 induction ~3-fold in WT and LVR isolated mPOA neurons, with no effect of the ERbeta-agonist DPN alone or in combination with PPT, suggesting medial-preoptic ERbeta activity may blunt ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	estrogen receptor 2	Rattus norvegicus	215-221	
19409966-5	2009	Our results further show that both ER subtypes are involved in the mediation of the synaptogenic effects of estrogens on VMNvl neurons since the administration of the selective ERalpha, propyl-pyrazole-triol (PPT), and ERbeta, diarylpropionitrile (DPN), agonists induced a significant increase in the number of synapses that, however, was more exuberant for PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	estrogen receptor 2	Rattus norvegicus	219-225	
19074580-8	2009	Ovariectomized young adult female Sprague Dawley rats treated with racemic DPN, S-DPN, and the ERbeta agonist, WAY-200070, showed significantly decreased anxiety-like behaviors in both the open-field and elevated plus maze and significantly less depressive-like behaviors in the forced swim test compared with vehicle-, R-DPN-, or propylpyrazoletriol (ERalpha agonist)-treated animals.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	331-350	estrogen receptor 2	Rattus norvegicus	95-101	
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	estrogen receptor 2	Rattus norvegicus	175-181	
25258388-9	2014	The oestrogenic signal was transmitted via ERA (ESR1) and ERB (ESR2) activation as administration of PPT and DPN resulted in 97 and 62%, respectively, elevation in Egr1 mRNA expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	estrogen receptor 2	Rattus norvegicus	63-67